News

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...
Indeed, SiteOne and at least 10 other developers want to follow in Vertex’s footsteps with their own medicines that stopper either the “NaV1.8” sodium ion channel, as Journavx does, or a ...
LiPF 6 integration into sodium-ion battery electrolytes strengthens solid electrolyte interphase (SEI) film and stabilizes O3 electrode surfaces, enhancing cycleability with 92.7% at 400 cycles ...
These studies indicated that sodium channel blockers might have an immunomodulatory action, and that a sodium-channel-blocker-induced attenuation of inflammation might contribute to the improved ...
Ion channels are integral membrane protein assemblies that modulate the flow of ions into and out of a cell or organelle, leading to generation of electrical signals. Opening (gating) of ion ...
In many lower-sodium salts like K-salt, the sodium is partially substituted with potassium. K-salt is set to hit supermarkets in early October 2022, and will retail at S$2.50 for a 400g pack.
"Its analgesic activity comes from binding to a sodium ion channel called NaV1.8, which is a hot target right now for the development of compounds to treat chronic pain," Sello says.
Risk of Hypotension With Concomitant Use of Calcium-Channel Blockers and Macrolide Antibiotics Amy Henneman; Krisy-Ann Thornby Disclosures Am J Health Syst Pharm. 2012;69 (12):1038-1043.
Nanjing Deheng Pharmaceutical Technology Co. Ltd. and Nanjing Delova Biotech Co. Ltd. have discovered new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for ...
Others working on sodium ion channel drugs for acute pain applications include Latigo Biotherapeutics, which raised $135 million in a Series A last year and has NaV1.8 inhibitors LTG-001 and LTG ...